Preclinically, its dual blockade achieves superior suppression of immunoglobulin-secreting cells compared to selective BLyS inhibition, potentially offering enhanced control over APRIL-driven IgA/IgG production and plasma cell longevity – key factors in LN pathogenesis. The gene discussed is TNFSF13B; the disease is lobular neoplasia.